Key facts
- Sava Technologies’s last known valuation is $55.9M (Dec 2024).
- It has raised $46.4M; the latest was Later Stage VC ($25.7M) in Jul 2025.
- Notable investors include Innovate UK, MassChallenge, SOSV, Joyance Partners, Balderton Capital — 24 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Sava Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Sava Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sava Technologies
Developer of biosensing technology designed to provide real-time feedback about the body's molecular signature. The company's technology offers continuous monitoring of glucose and lactate to train smarter, predict exhaustion, and provide optimal dietary plans, enabling athletes to get bodily information in real-time.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2016
- Employees
- 60
- Website
- sava.health/
- Ownership
- Privately Held (backing)
Sava Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sava Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sava Technologies in its N-PORT filings yet. We sweep new filings monthly.